A Postmarketing Pharmacovigilance Study of Fenfluramine: Adverse Event Data Mining and Analysis Based on the US Food and Drug Administration Public Data Open Project (openFDA)

被引:0
|
作者
Chen, Tianyu [1 ]
Chen, Qiying [2 ]
Zhang, Yuezhen [1 ]
Liu, Ting [1 ,2 ]
机构
[1] Quanzhou Med Coll, 950 Donghai St, Quanzhou 362000, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 2, 950 Donghai St, Quanzhou 362000, Fujian, Peoples R China
关键词
Fenfluramine; openFDA; Adverse events; Pharmacovigilance; DRAVET;
D O I
10.1016/j.pediatrneurol.2025.03.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: A postmarketing analysis of the adverse events (AEs) associated with fenfluramine (FFA) was conducted using the US Food and Drug Administration's Open Public Data Program (openFDA). Methods: The openFDA database was queried to retrieve FFA AE reports. Two algorithms, namely, the reporting odds ratio (ROR) and proportional reporting ratio, were employed for the purpose of detecting potential safety signals. Results: From the openFDA data platform, a total of 6,269,521 AE reports were collected during the study period; the number of AE reports with FFA as the primary suspect was 2386. Of these, 1526 (63.96%) were reported by consumers or non-health professionals, 2009 (84.20%) were reported by the United States, 1053 (44.13%) were unknown indications, and serious AEs were reported in 1315 cases (55.11%). A total of 62 signals were generated. The top 10 signals included atonic seizures (ROR of 918.52, 95% confidence interval [CI]: 670.65-1257.99), seizure clusters (ROR of 787.02, 95% CI: 595.26-1040.56), mitral valve thickening (ROR of 773.94, 95% CI: 463.47-1292.38), pulmonary valve incompetence (ROR of 600.71, 95% CI: 432.09-835.13), echocardiogram abnormal (ROR of 417.13, 95% CI: 307.87-565.16), change in seizure presentation (ROR of 287.55, 95% CI: 214.81-384.91), tricuspid valve incompetence (ROR of 221.42, 95% CI: 179.68-272.84), aortic valve incompetence (ROR of 176.59, 95% CI: 131.89-236.45), tonic convulsion (ROR of 173.68, 95% CI: 110.28-273.54), and myoclonic epilepsy (ROR of 158.05, 95% CI: 102.60-243.46). Conclusions: This study employed the openFDA database to identify safety signals associated with FFA, thereby offering significant insights for clinical monitoring and risk identification in patients undergoing FFA therapy. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:96 / 102
页数:7
相关论文
共 50 条
  • [41] A pharmacovigilance study of drug-reduced male semen quality based on the Food and Drug Administration adverse event reporting system database
    Tan, Haowen
    Luo, Luping
    Li, Wenjun
    Lan, Weiwei
    Chen, Ying
    Huang, Guili
    Yang, Jia
    Xi, Xin
    ANDROLOGY, 2025, 13 (02) : 217 - 225
  • [42] Estimating the extent of adverse event reporting to the US food and drug administration: A case-study of the statin-associated rhabdomyolysis data
    McAdams, Mara
    Staffa, Judy
    Dal Pan, Gerald
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S70 - S70
  • [43] Assessment of Reye's syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
    Matsumoto, Kiyoka
    Hasegawa, Shiori
    Nakao, Satoshi
    Shimada, Kazuyo
    Mukai, Ririka
    Tanaka, Mizuki
    Satake, Riko
    Yoshida, Yu
    Goto, Fumiya
    Inoue, Misaki
    Ikesue, Hiroaki
    Iguchi, Kazuhiro
    Hashida, Tohru
    Nakamura, Mitsuhiro
    SAGE OPEN MEDICINE, 2020, 8
  • [44] Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System
    Pundole, Xerxes
    Shah, Mohsin
    Abdel-Wahab, Noha
    Suarez-Almazor, Maria
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [45] Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database
    Wang, Lin-Yu
    Liao, Liu-Feng
    Lei, Cai-Lu
    Wu, Qiong
    Guo, You-Jia
    Li, Yan
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 833 - 839
  • [46] Analysis of Information on Drug Adverse Reactions Using US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Nango, Daisuke
    Sekizuka, Tuyoshi
    Goto, Makoto
    Echizen, Hirotoshi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (04): : 341 - 344
  • [47] Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials
    Federer, Callie
    Yoo, Minjae
    Tan, Aik Choon
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2016, 14 (10) : 357 - 366
  • [48] Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
    Harpaz, R.
    DuMouchel, W.
    Shah, N. H.
    Madigan, D.
    Ryan, P.
    Friedman, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (06) : 1010 - 1021
  • [49] Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
    Zheng, Yi
    Guo, Xiaojing
    Chen, Chenxin
    Chi, Lijie
    Guo, Zhijian
    Liang, Jizhou
    Wei, Lianhui
    Chen, Xiao
    Ye, Xiaofei
    He, Jia
    PHARMACEUTICALS, 2023, 16 (01)
  • [50] Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of US Food and Drug Administration Adverse Event Reporting System Data
    Umetsu, Ryogo
    Abe, Junko
    Ueda, Natsumi
    Kato, Yamato
    Matsui, Toshinobu
    Nakayama, Yoko
    Kinosada, Yasutomi
    Nakamura, Mitsuhiro
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (11) : 1689 - 1699